Bermekimab - XBiotech

Drug Profile

Bermekimab - XBiotech

Alternative Names: CA-18C3; CV-18C3; Human IGG1 monoclonal antibody specific for human interleukin-1 alpha; Hutruo; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 01 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XBiotech
  • Developer Cedars-Sinai Medical Center; Hellenic Institute for the Study of Sepsis; Ipsen; XBiotech
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • No development reported Haematological malignancies

Most Recent Events

  • 26 Oct 2018 XBiotech has patent protection for bermekimab for the treatment of dermatological pathologies and cancer-associated cachexia in Europe in the third quarter of 2018
  • 26 Oct 2018 XBiotech receives patent allowance for bermekimab for the treatment of cardiovascular disease and True HumanTM antibody discovery platform in Australia, Canada, Israel, Mexico, Philippines, Russia and South Korea in the third quarter of 2018
  • 26 Oct 2018 XBiotech plans a clinical trials for Cardiovascular disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top